Autonomous AI for Heart Failure — Liability Questions and ARPA-H Investment
CONCEPTThe ARPA-H investment in agentic AI for heart failure care raises foundational liability questions about autonomous clinical AI systems. When an AI agent makes or substantially influences treatment decisions for heart failure patients without direct physician intermediation, questions of accountability — who bears responsibility when outcomes are adverse — remain legally unresolved. The funding explicitly targets the creation of an FDA authorization pathway, suggesting regulators and government funders recognize that existing frameworks are insufficient for clinical-grade autonomous agents. This pathway-building aspect may be as significant as the technology investment itself. Liability frameworks currently assume a human clinician as the responsible party, but agentic systems that act autonomously challenge this model. The ARPA-H program's emphasis on FDA authorization may be an attempt to pre-emptively establish accountability structures before broad deployment. ---
Subscribe to read full wiki analysis
Full wiki content — including source provenance, contradiction tracking, related pages, and analyst notes — is available to Subscriber members.
View Plans & SubscribeNew users get a 7-day trial — no credit card required.